-Parties: The plaintiffs included Boehringer Ingelheim (Canada) Ltd. and Boehringer Ingelheim International GmbH. The defendant was Ascend Laboratories Ltd.

-Subject Matter: This Federal Court matter is a patent infringement action commenced by Statement of Claim under the Patented Medicines (Notice of Compliance) Regulations. The Plaintiffs allege that Ascend Laboratories Ltd.'s abbreviated new drug submission for generic empagliflozin tablets would infringe five Canadian patents associated with the Plaintiffs' JARDIANCE® product, and seek a declaration of infringement, a permanent injunction, and related relief. The case is ongoing and is currently being specially managed, with Associate Judge Trent Horne assigned as case management judge.

-Date: The hearing was set on July 10, 2026.

-Venue: This was a federal case before the Federal Court.

-Amount: No financial award was specified.